<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="ABATACEPT " rxcui="614391">
<ATC code="L04AA24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>as well as during the 3 months following the end of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)" code="MONANT" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal. </DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>-- belimumab, blinatumomab, canakinumab, obinutuzumab,ofatumumab, rituximab, tocilizumab, ustekinumab</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTI-TNF ALPHA" code="4ABO" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="BELATACEPT" rxcui="1112973">
<ATC code="L04AA28" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>--And during the 6 months following the end of the chemotherapy</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="DIMETHYL (FUMERATE OF)" rxcui="1373478">
<ATC code="N07XX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the risk of infection</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease. This risk is increased in older patients already immunodepressed by the underlying disease.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>In particular, use an inactive vaccine when one exists (poliomyelitis).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>With the exception of inhaled and local routes and for dosages greater than 10mg/day of prednisone equivalent (or &gt;2mg/kg/day with children or &gt;20 mg/day for children weighing more than 10 kg) for more than two weeks and for administration in &quot;bolus&quot; of the corticoids:

risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the corticotherapy</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="HYDROXYCARBAMIDE " rxcui="5552">
<ATC code="L01XX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>In its indication for the patient with drepanocytosis, theoretic risk of general fatal vaccine disease.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Administering these medications together should only be considered if the benefits are estimated to be superior to this risk.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE MOFETIL" >
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLATE" />
<ATC code="MOFETIL" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="7145" />
<ATC code="L04AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE SODIUM " rxcui="408142">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months after the end of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="TERIFLUNOMIDE" rxcui="1310520">
<ATC code="L04AA31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
